US Study Publication in the American Journal of Preventive Cardiology

Coronary Heart Disease (CHD) prevention nearly twice as effective when using CARDIO inCode
as method to target treatment

Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction.

Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.

Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction will be presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.

Company Announces Appointment of Veteran Healthcare Communications Entrepreneur and Digital Analytics Expert, Anna Walz, to Board

Lipid inCode® offers greater diagnostic information for hypercholesterolemia sufferers over current NHS standard

New look and logo to position Radcliffe as a multimedia knowledge network and global market leader for the cardiovascular community.

Commencement of regulatory pathway for U.S. market approval

Jason Powell joins as Non-Executive Director

Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction.

Using its patent-protected scale-based technology, PhysioWave brings Pulse Wave Velocity measurement to a large multi-factor performance study.

A new fund and new method of investing in medical device startups.

Congresswoman Donna Shalala to join leading scientists, developers, regulators, and policy/business decision-makers who are seeking to accelerate translation of major scientific discoveries into products that slow the aging process and onset of major chronic diseases.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio's Phase II clinical trial will be presented at the 2020 Congress of the European Society of Cardiology from August 29 through September 1.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled "Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial", the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208

350+ leaders of hospitals, health systems and cardiology departments weigh in on top trends in heart care and where they wish to take it

Recardio Inc., a clinical-stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Patient recruitment continues at all participating centers.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and U.S. centers.

U.S. medical biomimetics market dominated North America region with more than 90% revenue share in 2018 and is anticipated to achieve significant CAGR from 2019 to 2025 owing to growing burden of chronic diseases.

North America next generation sequencing market surpassed USD one billion in 2018 and is expected to register a lucrative CAGR from 2019 to 2025, driven by increasing prevalence of cancer and genetic diseases

According to a new market research report launched by Inkwood Research, the Global Vascular Stents Market is growing at a CAGR of 7.84% during the forecast period 2018-2026, The Global Vascular Stents Market was valued at 1.32 billion in 2017 and is anticipated to reach around $ 2.5 billion by 2026, growing at an estimated CAGR of 7.84%, during the forecast period 2018-2026.

CADence Named Best New Product of the Year in Healthcare

"Metabesity" names target and serves as a call to action

Creators of RealPatientsSpeak Capture Event Highlights for a Close "UP" Look at Patient Centricity: The Present and Future Outlook

US Cardiology Review Relaunches and Announces the Appointment of Professor Donald E Cutlip as Editor-in-Chief.

Molecular Innovations, Inc. has been issued United States Patent Number 9,085,795 for its unique and novel "Human Prorenin ELISA Kit."

ide Group is pleased to announce the appointment of Marek Swoboda as part of ide's continued commitment to developing new opportunities and realising value across US markets. Marek's appointment marks an exciting phase of progress for ide, signifying an important step towards building a strong international base to deliver cutting edge technologies that make a difference and change lives.

An exciting new way to monitor your health and be warned about any potentially life-threatening problems is being introduced to the world on Indiegogo. This device, known as 'SmartCardio', monitors a person's cardiovascular system and alerts the wearer, their cardiologist and all emergency contacts before a health crisis can occur.

As an IOQ facility, South Nassau demonstrates excellence in care and a commitment to continuous improvement and is recognized in Aetna's DocFind® online provider directory.

Ratio of body fat to lean body mass critical identifier for higher risk of cardiovascular death.

Study found giving mice watermelon juice seemed to improve cardiovascular health.

Award winning Digisonics PACS was recently selected and implemented at Medical Faculty Associates in Washington D.C.

Digisonics reaches a new milestone with over 3,000 licenses sold to over 1,000 facilities.

Two biomedical measurement companies merge to offer fully integrated cardiovascular measurement solutions for both pre-clinical and clinical products.

VP of Research & Development Amar A. Sethi, MD, PhD Says NIH Study on Niaspan's Use With Other Cholesterol Drugs Should Be Seen As a Tentative Result

Commenting on these findings, Amar A. Sethi, MD, PhD, Vice President of Research and Development at PBI, said that therapy focused on increasing HDL-C is highly warranted.